

# GRIFOLS

**The company has concluded its debt refinancing process substantially improving all conditions**

## **Grifols refinances debt for USD 6.3 billion, reducing the margin to 200 bps and extending its maturities**

- **The refinancing process includes long-term syndicated debt with financial institutions and institutional investors in two tranches, the undrawn revolving credit facility and the term loan to finance the acquisition of Hologic's transfusion diagnostics business.**
- **This process optimizes the financial structure and significantly improves all financing conditions.**
- **The average cost of the refinanced debt is 2.65%.**
- **The margin of 200 basis points represents a reduction in the cost of debt close to 100 basis points. The average term of the debt is 7 years.**
- **The excellent acceptance in the international capital markets has enabled the refinancing to be concluded swiftly and with a significant over-subscription, reaffirming investors' confidence in Grifols.**

***Barcelona, February 6, 2017.-*** Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a global healthcare company with a track record of more than 75 years improving people's health and well-being and a leader in the production of plasma medicines, transfusion diagnostic systems and pharmaceutical specialties for hospital use, has concluded its debt refinancing process started on January 9, 2017, optimizing its debt structure, improving financing conditions in all tranches and extending maturities.

The refinancing process has been conducted in record time given the favorable acceptance that it has in the international capital markets and among investors and financial institutions, which understand and positively value the company's management and its growth policy, both organic and through strategic acquisitions. In this regard, 50 financial institutions have subscribed tranche A and 140 institutional investors tranche B.

The total amount of debt subject to this process is USD 6.3 billion (EUR 5.8 billion), including the long-term syndicated financing with financial institutions and institutional investors segmented into 2 tranches (Tranche A and Tranche B), the undrawn multi-currency revolving credit facility and the

# GRIFOLS

USD 1.7 billion of the term loan to finance part of the purchase of the Hologic's transfusion diagnostics business. The placement of USD 6.3 billion of senior secured debt was significantly over-subscribed, making it possible to improve the cost of the two tranches.

The average cost of the refinanced debt is 2.65%. The margin has been reduced by 100 bps and is at 200 bps, significantly improving the current conditions.

The refinancing has not included the USD 1 billion bond issue.

Financial structure of Grifols and the new conditions subsequent to the conclusion of the refinancing process:

STRUCTURE	AMOUNT (in millions)	NEW CONDITIONS
<b>TOTAL SENIOR SECURED DEBT</b>		
<i>Tranche A (TLA)</i>	USD 3,000	Interest rate: LIBOR + 175 bps Maturity: 2025 Quasi-bullet
<i>Tranche B (TLB)</i>	USD 3,000	Interest rate: LIBOR + 225 bps Maturity: 2023 Bullet
<i>Financing line (multi-currency revolving)</i>	USD 300	Interest rate: LIBOR + 175 bps Maturity: 2025
<b>TOTAL DEBT</b>	<b>6,300</b>	

Grifols is committed to rapidly reducing its leverage levels. The company plans to absorb the debt increase through a greater capability to generate cash flows. Historically, Grifols has a track record of deleveraging ability post acquisitions.

Subsequent to the acquisition of part of Hologic's transfusion business, its credit ratings from Standard & Poor's have remained unchanged. Moody's revised its credit ratings by one notch, while it maintains a "stable" outlook for the company.

The conclusion of the refinancing process has not entailed any variations and both ratings agencies have affirmed their credit ratings.

The current credit ratings are as follows:

	<i>Moody's</i>	<i>Standard &amp; Poor's</i>
<b>Corporate rating</b>	<i>Ba3</i>	<i>BB</i>
<b>Senior secured debt</b>	<i>Ba2</i>	<i>BB</i>
<b>Senior unsecured debt</b>	<i>B2</i>	<i>B+</i>
<b>Outlook</b>	<i>Stable</i>	<i>Stable</i>

## Advisors

Osborne Clarke, S.L.P. and Proskauer Rose, LLP have acted as legal advisors in the refinancing process, while Nomura, HSBC, Bank of America Merrill Lynch and Goldman Sachs were the bookrunners.

## About Grifols

Grifols is a global healthcare company with a track-record of more than 75 years improving people's health and well-being through the development of plasma protein therapies, hospital pharmacy products and diagnostic technology for clinical use.

The company is present in more than 100 countries worldwide and its headquarters are located in Barcelona, Spain. Grifols is a leader in plasma collection with a network of 160 plasma donation centers in the U.S., and is a leading producer of plasma-derived medicines. As a recognized leader in transfusion medicine, Grifols offers a comprehensive range of transfusion medicine, hemostasis, and immunoassay solutions for clinical laboratories, blood banks, and transfusion centers.

In 2015, sales exceeded EUR 3,930 million with a headcount close to 14,700 employees. Grifols demonstrates its commitment to scientific progress by allocating a significant portion of its annual income to R&D.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE: GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE: GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information, visit [www.grifols.com](http://www.grifols.com)

## **LEGAL DISCLAIMER**

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols Group.